Last reviewed · How we verify
anti-CD3 monoclonal antibody — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
anti-CD3 monoclonal antibody (anti-CD3 monoclonal antibody) — Inspira Medical AB.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anti-CD3 monoclonal antibody TARGET | anti-CD3 monoclonal antibody | Inspira Medical AB | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anti-CD3 monoclonal antibody CI watch — RSS
- anti-CD3 monoclonal antibody CI watch — Atom
- anti-CD3 monoclonal antibody CI watch — JSON
- anti-CD3 monoclonal antibody alone — RSS
Cite this brief
Drug Landscape (2026). anti-CD3 monoclonal antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cd3-monoclonal-antibody. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab